High-dose treatment of cathepsin B-activatable doxorubicin prodrug nanoparticles that induce tumor-specific immunogenic cell death for immunotherapy of melanoma with minimal systemic toxicity
Yoojeong Oh , Jinseong Kim , Nayeon Shim , Hyeonji Yoo , Hoyeon Lee , Yumin Jeong , Jagyeong Goo , Jeongyeon Lee , Mihee Jo , Hanhee Cho , Kwangmeyung Kim
Asian Journal of Pharmaceutical Sciences ›› 2026, Vol. 21 ›› Issue (1) : 101123
Highly potent chemotherapy provides rapid therapeutic efficacy in melanoma, but is often limited by drug resistance, off-target toxicity, and systemic toxicity. Combination therapy with chemotherapy and immunotherapy has attracted much attention but still faces challenges such as inconsistent immune responses and systemic toxicity. To address these limitations, we developed cathepsin B-activatable doxorubicin (DOX) prodrug nanoparticles (CatB-NPs) for inducing tumor-specific immunogenic cell death (ICD), while minimizing off-target toxicity in normal tissues with low cathepsin B expression. The cathepsin B- activatable DOX prodrug was synthesized by conjugating the cathepsin B-cleavable peptide (FRRL) to DOX, yielding FRRL-DOX. The amphiphilic FRRL-DOX formed stable nanoparticles (163.6 ± 13.5 nm) through intermolecular hydrophobic interaction and π- π stacking. In melanoma cells overexpressing cathepsin B, CatB-NPs effectively induced cancer cell- specific ICD, while sparing normal cells and immune cells. When CatB-NPs-treated B16F10 cells were co-cultured with immune cells, CatB-NPs enhanced the phagocytic activity of macrophages and induced the maturation of dendritic cells (DCs). In melanoma models, CatB-NPs passively accumulated at tumor tissues through the enhanced permeability and retention effect and were selectively activated by intratumoral cathepsin B, enabling high- dose treatment that induced robust ICD. Importantly, combination therapy with CatB-NPs and anti-PD-L1 antibody enhanced ICD, DC maturation and T-cell activation, resulting in complete tumor regression in 50% of treated mice by converting the immunosuppressive tumor environment into an immune-responsive state. In a lung metastasis model, high- dose CatB-NPs with anti-PD-L1 also suppressed metastatic burden without systemic toxicity, supporting their potential as a safe and effective chemo-immunotherapy for melanoma.
Cathepsin B-activatable prodrug / Doxorubicin / Melanoma / Immunogenic cell death / Immune checkpoint blockade / Chemo-immunotherapy
| [1] |
|
| [2] |
Fateeva A, Eddy K, |
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P, |
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
/
| 〈 |
|
〉 |